See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Runyuan Ji
Huai’an Key laboratory of Gastric Cancer, Jiangsu College of Nursing
Corresponding Author
ORCiD: https://orcid.org/0000-0002-3783-6229
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Dysregulation of miRNAs is involved in carcinogenesis of breast and may be used as prognostic biomarkers and therapeutic targets during cancer process. The purpose of this study was to explore the effect of miR-105-3p on tumourigenicity of breast cancer and its underlying molecular mechanisms.
Methods: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was applied to detect the expression of miR-105-3p in breast cancer tissues and cell lines. The impacts of miR-105-3p on proliferation, migration, invasion and apoptosis of human breast cancer cells (MCF-7 and ZR-75-30) were evaluated by CCK-8, transwell chamber assay, TUNEL assay and western blot assay, respectively. Besides, bioinformatics and luciferase reporter assay were used to find out the target genes of miR-105-3p.
Results: The expression of miR-105-3p was elevated in breast cancer tissues and increased along with tumor severity. Downregulation of miR-105-3p could inhibit cell proliferation, suppress cell migration/invasion, and promote cell apoptosis in MCF-7 and ZR-75-30 cells. Furthermore, Golgi integral membrane protein 4 (GOLIM4) was identified to be the direct target gene of miR-105-3p by bioinformatics and luciferase reporter assay. In addition, silencing of GOLIM4 could restore the anti-breast cancer effects induced by miR-105-3p downregulation.
Conclusions: MiR-105-3p acts an oncogene to promote proliferation and metastasis of breast cancer cell by targeting GOLIM4, which provides a new target for the prevention and treatment of breast cancer.
Keywords
miR-105-3p, breast cancer, GOLIM4, proliferation, migration
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
Version 3
Posted 05 Jan, 2021
No community comments so far
Editorial decision: Minor revision
On 08 Dec, 2020
Review #1 received
Received 02 Dec, 2020
Reviewers invited
Invitations sent on 29 Nov, 2020
Reviewer #1 agreed
On 29 Nov, 2020
Editor assigned
On 25 Nov, 2020
Submission checks complete
On 25 Nov, 2020
Editor invited
On 25 Nov, 2020
No comments provided
Editorial decision: Major revision
On 30 Oct, 2020
Review #3 received
Received 24 Oct, 2020
Reviewer #3 agreed
On 02 Oct, 2020
Review #2 received
Received 01 Oct, 2020
Reviewers invited
Invitations sent on 01 Oct, 2020
Reviewer #1 agreed
On 01 Oct, 2020
Reviewer #2 agreed
On 01 Oct, 2020
Review #1 received
Received 01 Oct, 2020
Editor assigned
On 30 Sep, 2020
Submission checks complete
On 29 Sep, 2020
Editor invited
On 29 Sep, 2020
No comments provided
Editorial decision: Major revision
On 24 Jul, 2020
Review #1 received
Received 22 Jul, 2020
Review #3 received
Received 22 Jul, 2020
Review #2 received
Received 07 Jul, 2020
Reviewer #2 agreed
On 06 Jul, 2020
Reviewer #3 agreed
On 06 Jul, 2020
Reviewers invited
Invitations sent on 02 Jul, 2020
Reviewer #1 agreed
On 02 Jul, 2020
Editor assigned
On 25 Jun, 2020
First submitted
On 24 Jun, 2020
Submission checks complete
On 24 Jun, 2020
Editor invited
On 24 Jun, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Runyuan Ji
Huai’an Key laboratory of Gastric Cancer, Jiangsu College of Nursing
Corresponding Author
ORCiD: https://orcid.org/0000-0002-3783-6229
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
Version 3
Posted 05 Jan, 2021
No community comments so far
Editorial decision: Minor revision
On 08 Dec, 2020
Review #1 received
Received 02 Dec, 2020
Reviewers invited
Invitations sent on 29 Nov, 2020
Reviewer #1 agreed
On 29 Nov, 2020
Editor assigned
On 25 Nov, 2020
Submission checks complete
On 25 Nov, 2020
Editor invited
On 25 Nov, 2020
No comments provided
Editorial decision: Major revision
On 30 Oct, 2020
Review #3 received
Received 24 Oct, 2020
Reviewer #3 agreed
On 02 Oct, 2020
Review #2 received
Received 01 Oct, 2020
Reviewers invited
Invitations sent on 01 Oct, 2020
Reviewer #1 agreed
On 01 Oct, 2020
Reviewer #2 agreed
On 01 Oct, 2020
Review #1 received
Received 01 Oct, 2020
Editor assigned
On 30 Sep, 2020
Submission checks complete
On 29 Sep, 2020
Editor invited
On 29 Sep, 2020
No comments provided
Editorial decision: Major revision
On 24 Jul, 2020
Review #1 received
Received 22 Jul, 2020
Review #3 received
Received 22 Jul, 2020
Review #2 received
Received 07 Jul, 2020
Reviewer #2 agreed
On 06 Jul, 2020
Reviewer #3 agreed
On 06 Jul, 2020
Reviewers invited
Invitations sent on 02 Jul, 2020
Reviewer #1 agreed
On 02 Jul, 2020
Editor assigned
On 25 Jun, 2020
First submitted
On 24 Jun, 2020
Submission checks complete
On 24 Jun, 2020
Editor invited
On 24 Jun, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
Background: Dysregulation of miRNAs is involved in carcinogenesis of breast and may be used as prognostic biomarkers and therapeutic targets during cancer process. The purpose of this study was to explore the effect of miR-105-3p on tumourigenicity of breast cancer and its underlying molecular mechanisms.
Methods: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was applied to detect the expression of miR-105-3p in breast cancer tissues and cell lines. The impacts of miR-105-3p on proliferation, migration, invasion and apoptosis of human breast cancer cells (MCF-7 and ZR-75-30) were evaluated by CCK-8, transwell chamber assay, TUNEL assay and western blot assay, respectively. Besides, bioinformatics and luciferase reporter assay were used to find out the target genes of miR-105-3p.
Results: The expression of miR-105-3p was elevated in breast cancer tissues and increased along with tumor severity. Downregulation of miR-105-3p could inhibit cell proliferation, suppress cell migration/invasion, and promote cell apoptosis in MCF-7 and ZR-75-30 cells. Furthermore, Golgi integral membrane protein 4 (GOLIM4) was identified to be the direct target gene of miR-105-3p by bioinformatics and luciferase reporter assay. In addition, silencing of GOLIM4 could restore the anti-breast cancer effects induced by miR-105-3p downregulation.
Conclusions: MiR-105-3p acts an oncogene to promote proliferation and metastasis of breast cancer cell by targeting GOLIM4, which provides a new target for the prevention and treatment of breast cancer.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Loading...